Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Published On: 2 June 2023

  • Developing new ways to treat nerve damage and chronic pain using the body’s own proteins

    Sinfonia Biotherapeutics uses the body’s reparative proteins to develop effective [...]

  • SISP deepens innovation collaboration in Flemingsberg

    During the spring, Flemingsberg Science approached Swedish Incubators and Science [...]

  • Life Tech guides companies to the region’s research infrastructures

    The Stockholm Life Tech project achieved its goal in the [...]

  • Breakthrough for AlzeCure in the development of drugs for nerve pain

    AlzeCure Pharma shows positive results from its clinical study with [...]

  • From Science Week: Innovative arenas create collaboration for the city of the future

    See the panel discussion on how innovative neutral arenas are central to the development of the smart and knowledge-intensive city. Flemingsberg Science CEO Johnny Högberg participates together with a panel consisting of Sophia Sundberg, CEO, Barkaby Science, Peter Dobers, Professor of Business Administration with a focus on sustainable development and collaboration, Södertörn University, Johan Zachrisson, Business Development Manager, Fabege and Anton Västberg, Development Director, Region Stockholm.